Post by Allucent

As precision oncology evolves, liquid biopsy and ctDNA are playing an increasingly central role in patient selection, minimal residual disease (MRD) detection, and treatment monitoring across solid tumor trials. For small and mid-size biopharma sponsors, this evolution creates new opportunities to design smarter oncology trials. It also introduces additional considerations around assay validation, endpoint selection, regulatory expectations, and operational execution. In a recent blog, Gert Bluschke, MD-PhD, explores how liquid biopsy is shaping solid tumor development, including the emerging role of ctDNA in clinical trial design and decision-making. Read the blog to learn what sponsors should consider as ctDNA continues to gain momentum in precision oncology: https://lnkd.in/ePnK_Amn #Allucent #BringingNewTherapiesToLight #PrecisionOncology #LiquidBiopsy #ctDNA #OncologyClinicalTrials #OncologyCRO